Scott Applebaum

Chief Legal Officer & Chief Business Officer at VectivBio

Speaker

Scott Applebaum was most recently the Chief Legal Officer and Chief Business Officer of VectivBio AG, a clinical stage biotech focused on the discovery, development and commercialization of innovative treatments for severe rare conditions. Mr. Applebaum led the sale of VectivBio to Ironwood Pharmaceuticals for $1.2B in 2023. He has more than 25 years of legal, regulatory and operational experience in the pharmaceutical industry.

Prior to joining VectivBio, Mr. Applebaum was the Chief Legal & Compliance Officer and SVP of Regulatory Affairs at Trevena, where he played a key role in gaining FDA approval for their only commercial product. Previously, he served as President of Context Therapeutics and was General Counsel at Vitae Pharmaceuticals, where he was instrumental in their sale to Allergan. Formerly, he was Chief Legal Officer for Medgenics, a rare genetic disease company. Mr. Applebaum spent 10 years at Shire, where his roles included leading its global Legal Group, global Neuroscience Business Unit, and global Regulatory Affairs, Quality Assurance and Compliance function. He began his career in the industry at Bristol Myers Squibb Company.

Prior to his career in the pharmaceutical industry, Mr. Applebaum was a lawyer at Dechert LLP in Philadelphia. He received a J.D. from Stanford Law School and a B.S. in Economics, Finance and Accounting from the Wharton School of the University of Pennsylvania.